source: ag-IP news

CAMBRIDGE, MA - Idera Pharmaceuticals Inc. announced in a Wednesday press release the issuance of US patent 7,262,286 (the ‘286 patent) for novel immunostimulatory oligonucleotide compositions.

The claims of this patent, entitled “Modulation of Immunostimulatory Activity of Immunostimulatory Oligonucleotide Analogs by Positional Chemical Changes” cover oligonucleotide compounds comprising a synthetic immunostimulatory dinucleotide motif.

The claimed dinucleotide motifs contain certain analogs of cytosine together with guanosine or certain analogs of guanosine.

“With the issuance of claims of the ‘286 patent, we have expanded our patent portfolio covering synthetic dinucleotide motifs for use in our Toll-like Receptor (TLR) 9-targeted compounds,” CEO and Chief Scientific Officer Sudhir Agrawal, D. Phil said.

Presently, the company has over 200 patents and patent applications world-wide covering agonists and antagonists of TLR7, 8 and 9.

Idera Pharmaceuticals is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use as vaccine adjuvants.